S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:CNTG

Centogene (CNTG) Stock Price, News & Analysis

$0.92
+0.07 (+8.33%)
(As of 03:57 PM ET)
Today's Range
$0.88
$0.93
50-Day Range
$0.84
$1.26
52-Week Range
$0.61
$2.52
Volume
9,735 shs
Average Volume
16,160 shs
Market Capitalization
$24.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Centogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
62.9% Upside
$1.50 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.26
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.60) to ($0.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.96 out of 5 stars

Medical Sector

206th out of 939 stocks

Medical Laboratories Industry

8th out of 22 stocks


CNTG stock logo

About Centogene Stock (NASDAQ:CNTG)

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

CNTG Stock Price History

CNTG Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
CENTOGENE Announces Preliminary Full Year 2023 Revenue
Centogene NV Ordinary Shares CNTG
Dangerous Bank Change (3 steps to protect yourself)
In July of this year, the US government made a sweeping change to bank accounts nationwide.  It gave them unheard-of powers to control your bank account. They can now closely track every transaction. They could even freeze it. Unless you protect yourself today. Fortunately, there are 3 simple steps you can take to safeguard your savings.
EVER, BIVI and CNTG among mid-day movers
H.C. Wainwright Keeps Their Buy Rating on Centogene NV (CNTG)
CENTOGENE Reports First Half 2023 Financial Results
See More Headlines
Receive CNTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/24/2021
Today
2/23/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CNTG
Fax
N/A
Employees
444
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
+62.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50.03 million
Book Value
$0.29 per share

Miscellaneous

Free Float
26,559,000
Market Cap
$24.94 million
Optionable
Not Optionable
Beta
-0.73
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Ms. Kim Stratton (Age 62)
    CEO & Member of Management Board
    Comp: $930.31k
  • Mr. Jose Miguel Coego Rios
    CFO, Legal & IT and Member of Management Board
  • Dr. Peter Bauer M.D. (Age 54)
    Chief Medical & Genomic Officer and Member of Management Board
    Comp: $185.85k
  • Dr. Andrin Oswald M.D. (Age 52)
    Ph.D., Advisor
    Comp: $941.12k
  • Mr. Ian Rentsch
    Chief Commercial Officer & GM of Pharma














CNTG Stock Analysis - Frequently Asked Questions

Should I buy or sell Centogene stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTG shares.
View CNTG analyst ratings
or view top-rated stocks.

What is Centogene's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Centogene's shares. Their CNTG share price targets range from $1.50 to $1.50. On average, they expect the company's share price to reach $1.50 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for CNTG
or view top-rated stocks among Wall Street analysts.

How have CNTG shares performed in 2024?

Centogene's stock was trading at $1.20 at the beginning of the year. Since then, CNTG stock has decreased by 23.3% and is now trading at $0.9208.
View the best growth stocks for 2024 here
.

Are investors shorting Centogene?

Centogene saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 8,100 shares, a decline of 87.5% from the January 15th total of 64,700 shares. Based on an average trading volume of 15,700 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the stock are sold short.
View Centogene's Short Interest
.

When is Centogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our CNTG earnings forecast
.

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) issued its quarterly earnings data on Wednesday, November, 24th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.49. The business earned $35.60 million during the quarter, compared to analyst estimates of $31.91 million. During the same quarter last year, the company earned ($0.32) earnings per share.

What guidance has Centogene issued on next quarter's earnings?

Centogene issued an update on its FY 2023 earnings guidance on Thursday, January, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $52.2 million-$52.7 million, compared to the consensus revenue estimate of $57.6 million.

What other stocks do shareholders of Centogene own?
When did Centogene IPO?

(CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

How do I buy shares of Centogene?

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTG) was last updated on 2/23/2024 by MarketBeat.com Staff